GUBamy dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
GUBamy is a long-lasting amylin drug from Gubra. One early safety study in 76 people, paid for by AbbVie, has finished. No result from it, and no other human or animal data, has been published. PubMed holds zero records for it. Weight loss figures going around for it could not be traced to any real source.
Evidence grade for GUBamy: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 1 registered with no result. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 registered with no result
1 effects reported, 1 unwanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
GUBamy is a long-lasting copy of amylin, a hormone that helps you feel full. It comes from a Danish company, Gubra, and AbbVie ran its first study. Nothing about what it does in people has been published. It is not approved.
What people take it for
- Weight loss.
- Feeling full sooner and eating less.
What studies in people showed
One early safety study in 76 people finished in January 2026. It checked side effects and blood tests, not weight. No results have been posted. There are zero papers on it in PubMed. Some websites list weight loss numbers for it. We could not trace those numbers to any study at all.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No results in people have been posted, so its side effects in people are not known.
Where these come from: There are no user reports or posted human results on this page to draw from.
My bottom line
There is no result here, only a study number. If you see a weight loss percentage for this, ask where it came from. This page could not find a source for one.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 4 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is GUBamy?
GUBamy is a long-lasting amylin drug from Gubra. One early safety study in 76 people, paid for by AbbVie, has finished. No result from it, and no other human or animal data, has been published. PubMed holds zero records for it. Weight loss figures going around for it could not be traced to any real source.
GUB014295, called GUBamy by the company that made it, is a long-lasting copy of amylin. Amylin is a hormone the pancreas releases along with insulin. It slows how fast the stomach empties, holds back glucagon and helps you feel full. The Danish company Gubra discovered it. The one registered study lists AbbVie as the lead sponsor. It belongs to the same family as cagrilintide, petrelintide and eloralintide, which all now have published human data. GUBamy does not.
What exists is a single registry record. NCT06144684 is a two-part first test in people, at one site in the United Kingdom. People were assigned by chance to the drug or a dummy injection, and nobody knew which. Part one gave single rising doses to men who were lean, overweight or obese but otherwise healthy. Part two gave repeated rising doses to men and women. It began on 29 November 2023 and finished on 5 January 2026, with 76 people. Its main goals were safety measures: side effects, vital signs and lab tests. How the body handles the drug, and what it does, come second. No results have been posted on the registry. A PubMed search for GUBamy or GUB014295 on 11 September 2026 found nothing at all. None of three 2026 reviews of the amylin drug family names it in its summary.
So the honest content of this page is short. It covers how this drug family works, who the sponsor is, one finished 76 person safety study, and the fact that no results of any kind have been published. Some commercial peptide websites list weight loss percentages for GUBamy. They could not be traced to any study record, paper, conference summary or regulator document, and they are not repeated here.
How does GUBamy work?
Amylin works through receptors built from the calcitonin receptor paired with helper proteins (RAMPs). They sit in the hindbrain, in an area called the area postrema, and elsewhere. Switching them on slows the stomach, holds back glucagon after meals, and helps you stop eating sooner. Natural amylin clumps together and lasts only minutes. Long-lasting versions are built to resist clumping, and to stick to albumin or carry a fat chain, so they can be given once a week. Some drugs in this family act only on amylin receptors. Others also switch on the calcitonin receptor directly. No primary source found for this page says which kind GUB014295 is. So it is described only as its study record describes it: a long-lasting amylin copy. Nothing about how GUB014295 itself works, which receptors it hits, how long it lasts, or what it does in people or animals has been published.
What have studies in people found about GUBamy?
One finished early safety study in 76 healthy, overweight or obese volunteers, paid for by AbbVie, with no results posted or published. No public source has any human data on whether it works.
- NCT06144684: 76 people, assigned by chance to the drug or a dummy injection, single and repeated rising doses, finished January 2026. Its main goals were safety only. No results posted.
What this does not tell you: Nothing can be said about whether it works, how well people tolerate it, the dose, how long it lasts, or its effect on weight in people. Nothing has been reported. An early study built to check safety was not designed to show weight loss, even if its data were public. Any specific number tied to GUBamy that is going around has no source.
The state of the research
GUBamy's record is thin for an ordinary reason: it is early. Its first test in people finished in January 2026. Results from studies like that usually appear at conferences and in journals over the next one to two years, if the sponsor chooses to publish. AbbVie sponsoring a Gubra drug puts it inside a large company's pipeline. There, what gets shared and when is driven by business timing, not by when the science is done.
This page exists despite the empty record because of the numbers that float around without it. Commercial peptide websites attach weight loss percentages to GUBamy. The research for this page checked PubMed, ClinicalTrials.gov and three 2026 reviews of the drug family that looked at press releases and conference summaries. It found no source for any such figure. Until a study result is posted or published, the correct statement is that no result on whether it works has been reported. If you see a percentage, ask where it came from.
The evidence, in charts
Fig. 1a · how many people
1study in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
1 of 4 sources here is a study in people. The rest are not.
- Study in people · done in people125%
- Review of studies · sums up other studies375%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for GUBamy, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
The first test of this compound in people has finished and published nothing. 76 people took single and then repeated shots under the skin, at a single site in the United Kingdom. Nobody involved knew who got the drug. It ran from late 2023 to January 2026. What it measured was safety: side effects, vital signs and blood tests. AbbVie is the sponsor. No results have been posted, so nothing at all is known about what this does in a person.
Phase 1, randomised, double-blind, placebo-controlled, single then multiple ascending subcutaneous doses, single centre, United Kingdom. Lead sponsor AbbVie. Started 29 November 2023, completed 5 January 2026, 76 participants. Primary outcomes: adverse event incidence, vital signs, safety laboratory values. The record describes GUB014295 as a long-acting amylin analogue. No results posted.
- Review of studies2026Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
A review of long-lasting amylin-type drugs, covering pramlintide, cagrilintide, CagriSema, amycretin, eloralintide, petrelintide, Met-233 and AZD6234. Its summary does not mention GUB014295 or GUBamy.
Class review covering pramlintide, cagrilintide, CagriSema, amycretin, eloralintide, petrelintide, Met-233 and AZD6234. Its abstract does not mention GUB014295 or GUBamy.
- Review of studies2026Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
A review of long-lasting amylin drugs. It compares drugs that hit only amylin receptors with drugs that also hit the calcitonin receptor, on nausea and how easy they are to take. Its summary does not mention GUB014295.
Class review of long-acting amylin agents (cagrilintide, eloralintide, petrelintide, NN1213) and the distinction between selective amylin receptor agonists and dual amylin and calcitonin receptor agonists in relation to nausea and tolerability. Its abstract does not mention GUB014295.
- Review of studies2026Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials
A review of amylin drugs approved or being tested in people as of 30 April 2026. It drew on papers, registries, press releases and conference summaries. Its summary does not name GUB014295 or GUBamy.
Narrative review of amylin-based therapies approved or in human development as of 30 April 2026, drawing on publications, registries, press releases and congress abstracts. Its abstract does not mention GUB014295 or GUBamy by name.
Where to buy GUBamy
No seller we track lists GUBamy yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has GUBamy been tested in people?
Not in a completed trial cited here. 1 registered with no result. GUBamy is a long-lasting amylin drug from Gubra. One early safety study in 76 people, paid for by AbbVie, has finished. No result from it, and no other human or animal data, has been published. PubMed holds zero records for it. Weight loss figures going around for it could not be traced to any real source.
What is the GUBamy dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 registered with no result
Is GUBamy FDA-approved?
Not approved. One early safety study is finished (NCT06144684, 76 people, run by AbbVie). It mainly measured safety. No results posted and nothing published.
What is GUBamy?
GUB014295 is a long-lasting copy of the hormone amylin, discovered by Gubra. It is in the same family as cagrilintide and petrelintide. Its one study, an early safety test in 76 volunteers, lists AbbVie as sponsor. It is still being tested and is not approved anywhere.
How much weight loss does it produce?
No published or posted result answers that. The only study finished in January 2026, with safety as its main goal, and has posted no results. Percentages linked to GUBamy on commercial websites could not be traced to any study record, paper, conference summary or regulator document.
Is there any published research on it?
Not under either name. A PubMed search for GUBamy or GUB014295 on 11 September 2026 found zero records. None of three 2026 reviews of the amylin drug family names it in its summary. The ClinicalTrials.gov record is the only primary source.